Talis Other Stockholder Equity from 2010 to 2024
| TLIS Stock | USD 8.62 0.12 1.41% |
Other Stockholder Equity | First Reported 2010-12-31 | Previous Quarter 609.1 M | Current Value 639.5 M | Quarterly Volatility 294 M |
Check Talis Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Talis Biomedical's main balance sheet or income statement drivers, such as Net Interest Income of 50.4 K, Interest Income of 50.4 K or Depreciation And Amortization of 3.2 M, as well as many indicators such as Price To Sales Ratio of 34.51, Dividend Yield of 0.0 or PTB Ratio of 0.21. Talis financial statements analysis is a perfect complement when working with Talis Biomedical Valuation or Volatility modules.
Talis | Other Stockholder Equity |
Latest Talis Biomedical's Other Stockholder Equity Growth Pattern
Below is the plot of the Other Stockholder Equity of Talis Biomedical Corp over the last few years. It is Talis Biomedical's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Talis Biomedical's overall financial position and show how it may be relating to other accounts over time.
| Other Stockholder Equity | 10 Years Trend |
|
Other Stockholder Equity |
| Timeline |
Talis Other Stockholder Equity Regression Statistics
| Arithmetic Mean | 151,850,847 | |
| Coefficient Of Variation | 193.62 | |
| Mean Deviation | 245,973,108 | |
| Median | 3,810,000 | |
| Standard Deviation | 294,015,578 | |
| Sample Variance | 86445.2T | |
| Range | 866.1M | |
| R-Value | 0.70 | |
| Mean Square Error | 48060.7T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 45,726,025 | |
| Total Sum of Squares | 1210232.2T |
Talis Other Stockholder Equity History
About Talis Biomedical Financial Statements
Talis Biomedical shareholders use historical fundamental indicators, such as Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Talis Biomedical investors may analyze each financial statement separately, they are all interrelated. The changes in Talis Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses on on Talis Biomedical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Stockholder Equity | 609.1 M | 639.5 M |
Pair Trading with Talis Biomedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Talis Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Talis Biomedical will appreciate offsetting losses from the drop in the long position's value.Moving against Talis Stock
| 0.53 | EW | Edwards Lifesciences Corp | PairCorr |
| 0.47 | LH | Laboratory | PairCorr |
| 0.43 | DH | Definitive Healthcare | PairCorr |
| 0.42 | VREX | Varex Imaging Corp Fiscal Year End 12th of November 2024 | PairCorr |
| 0.4 | CI | Cigna Corp | PairCorr |
The ability to find closely correlated positions to Talis Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Talis Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Talis Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Talis Biomedical Corp to buy it.
The correlation of Talis Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Talis Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Talis Biomedical Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Talis Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Talis Stock Analysis
When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.